Targeted COVID-19 Leverage ExeVir’s ongoing focus on COVID-19 therapeutics and variant-proof XVR013m to position solutions for immunocompromised and elderly populations who require long-acting protection beyond vaccines.

Dengue Expansion Explore partnerships and licensing opportunities around dengue therapies, tapping into ExeVir’s VHH-Fc platform to address a high-need infectious disease with alignment to global health initiatives.

Pandemic Preparedness Offer shared risk programs or collaborations centered on pandemic preparedness assets, highlighting ExeVir’s modular VHH-Fc platform as a scalable approach for rapid development of broad-spectrum antibodies.

Strategic Partnerships Position ExeVir as a potential collaboration target for pharma companies seeking lightweight, cost-effective, stable antibody formats to complement or augment existing monoclonal pipelines.

Early-Stage Tech Value Highlight the advantages of VHH-Fc constructs—stability, ease of production, multi-specificity—when pitching early licensing, co-development, or strategic investment deals to biotech funds and potential licensees.